(EMAILWIRE.COM, November 25, 2008 ) HAMPTON, VA, November 25, 2008 -- HST Global, Inc. (OTCBB: HSTC), an integrated biotechnology and wellness company, today announced plans for the first quarter fiscal 2009.

The growing acceptance of alternative cancer treatments worldwide has placed HST Global in perfect position to launch a wholly owned division dedicated to opening our own brand of Cancer Treatment Centers. While we continue to look for in-licensing pre-clinical drug candidates, this strategy will enable the company to address the challenges individuals face in the treatment of cancer in the later stages.

Ronald Howell, President and CEO of HST Global, Inc. stated “There is a growing population of individuals experiencing the lack of available alternatives in treating late stage cancer. We have been working with a number of highly visible Physicians that are and have developed successful protocols that are meeting with success in the treatment of this population. As such, we will begin opening a privately branded chain of Cancer Treatment Centers strategically positioned around the world through a new wholly owned subsidiary.”

Mr. Howell went on to say, “The distribution channel established through our Cancer Treatment Centers will serve as a platform for implementing existing technologies and serve to identify appropriate communities for treatment with new and emerging drug candidates as they become available.”

Cancer is an epidemic that is worldwide and one that does not discriminate. HST Global, Inc. has been involved with pre-clinical and proven drug candidates that have shown high efficacy in the treatment of various cancers. The success and high efficacy achieved in these treatments has given the company a position of visibility that has attracted a number of International partners that want to move forward and open Centers worldwide. Movement to establish a global chain of Cancer Treatment Centers will provide an immediate revenue stream to the company.

Given the current negotiations HST believes:

• The Company will open its first corporate owned center in the first quarter 2009.
• The Company will open five partner centers worldwide in fiscal 2009.
• The annual estimated revenue stream from each individual clinic is projected to be between 8 - 10 million dollars per year.
• The Company will continue to seek out revolutionary and innovative products for the treatment of cancer and other life threatening diseases.

Due to the unfortunate nature of cancer, the Company is not as affected by current and/or future economic conditions. The Company’s intention is to provide World-Class treatment of this and other life threatening diseases.


About HST Global, Inc.

HST Global, Inc. is a development stage biotechnology company that acquires and develops innovative products for the treatment of cancer and other life threatening illnesses. We focus on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer, then developing those drug candidates for commercial use and developing a network of Wellness Centers Worldwide.
HST Global, Inc
Investor Relations
Wesley Tate, 757-766-6100
ir@hstglobal.com
www.hstglobal.com

HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


About StockProfit.com

StockProfit.com specializes in using technical analysis to identify stocks in particularly powerful up-trends, then pinpoint the optimal time to enter these stocks. Additionally, StockProfit.com is an online resource for aggressive risk-tolerant market participants who wish to learn about select growth companies and other ideas that could offer potentially superior investment returns. Research and due diligence tools such as Company Profiles, Technical Trading Alerts, detailed investment opinion reports, and regular email updates of Featured Companies are some of the services we provide to our readership. For more information, visit http://www.stockprofit.com


Disclaimer: Copyright© 2008 StockProfit™. All rights reserved. StockProfit™ is an independent electronic publication providing information on select public companies. StockProfit™ is not a registered investment advisor or broker-dealer. There is a risk of loss in all of trading. Past performance is no indication, nor guarantee of future results. The information contained herein is believed to be accurate. This update is provided as an information service only, and the statements and opinions in this update should not be construed as an offer or solicitation to buy or sell any security. In no event shall StockProfit™ and/or its publisher, Stock Services LLC or any of its employees or affiliates, be liable for any direct, incidental, consequential, indirect or punitive damages whatsoever arising out of the use of the Information, or for any errors or omissions in the content thereof, including, but not limited to, from any investment loss, damage or expense incurred by any investor resulting from the Information, or from the purchase or sale of any profiled company or any company which we make commentary. We recommend using good-'till-cancelled stop orders to minimize losses in the event of an adverse price movement. We have been compensated $ 2,500 and have received 35,120 Rule 144 shares by the Company for Profile Coverage. For further information, please visit http://www.stockprofit.com/disclaimer/

CONTACT: Alan Klitenic, Stock Services LLC, TEL: 818 334 4469 EMAIL: amk@stockprofit.com

Contact Information:
P.A. Relations
Alan Klitenic
Tel: 818-334-4469
Email us